Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056896 · ClinicalTrials.gov registry record · Early Phase 1
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
A Early Phase 1 study of Colorectal Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT05056896: Active Early Phase 1 study of Colorectal Cancer, sponsored by Massachusetts General Hospital.
NCT05056896 is a Early Phase 1 study of Colorectal Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 161 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056896, a Early Phase 1 study of Colorectal Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: * Low Dose Aspirin
Primary Outcome
All patients with available pre- and post-treatment samples containing high-quality RNA sequencing reads from at least 1,000 EPCAM+ single cells per time point were included in the analysis. Single cells were clustered according to cell type. The proportion (%) of cells expressing LGR5 (LGR5+), an accepted intestinal stem cell (ISC) marker of cell stemness, among the ISC cluster was calculated for each participant at each time point. The change in proportion of LGR5+ ISCs within each individual
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Aspirin
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What the registry record for NCT05056896 still lists
NCT05056896 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05056896 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05056896 about?
NCT05056896 is a clinical study titled "ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension". This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: * Low Dose Aspirin
What is the current status of trial NCT05056896?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 161 participants. The study started on 2022-06-03. Estimated completion is 2026-12-31.
What conditions does trial NCT05056896 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05056896?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG).
Who is sponsoring clinical trial NCT05056896?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056896 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056896's enrollment target sits among peer trials
161 165th of 381 higher than 216 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI